Advertisement

Imaging and dosimetry determinations using radiolabeled antibodies

  • Jorge Carrasquillo
Part of the Cancer Treatment and Research book series (CTAR, volume 68)

Abstract

Once the diagnosis of lymphoma is made, patients generally undergo an extensive diagnostic evaluation. This staging evaluation has prognostic implications and is important in the selection of therapy [1]. Staging involves invasive and noninvasive procedures [2], such as biopsies, laparotomy, plain radiographs, computerized tomography, ultrasound, magnetic resonance imaging, lymphangiography, and gallium scans. Many of these conventional radiographic techniques identify tumors based on physical characteristics, including density changes, mass effect, sonic characteristics, size, and location. Although useful, these modalities [3] lack specificity and only provide indirect evidence of tumor. Since the discovery of antibodies and the hybridoma technology [4], the development of radiolabeled anti-tumor monoclonal antibodies (MoAb) as imaging and therapeutic reagents promises to add an element of specificity not previously available with conventional techniques.

Keywords

Chronic Lymphocytic Leukemia Gamma Camera Diagnostic Dose Chronic Lymphocyte Leukemia Medical Internal Radiation Dosimetry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chabner BA, Johnson RE, Young RC, et al. Sequential nonsurgical staging of non-Hodgkin’s lymphoma. Ann Med 85:149–154, 1976.Google Scholar
  2. 2.
    Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31:1860–1861, 1971.PubMedGoogle Scholar
  3. 3.
    Hamlin J. Radiographic approach to the staging of lymphoma, including Hodgkin’s disease. In: Lymphoma, 1, JM Bennett (ed). Martinus Nyijhoff Publishers, Boston, 1981, pp. 1, 177-233.Google Scholar
  4. 4.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497, 1975.PubMedCrossRefGoogle Scholar
  5. 5.
    Carrasquillo JC. Radioimmunoscintigraphy with polyclonal or monoclonal antibodies. In: Antibodies in Radiodiagnosis and Therapy, M Zalutsky (ed). CRC Press, Boca Raton, FL, 1989, pp. 169–19.Google Scholar
  6. 6.
    Sfakianakis GN, Garty II, Serafini AN. Radioantibodies for the diagnosis and treatment of cancer; radioimmunoimaging (RAI) and radioimmunotherapy (RAT). Cancer Invest 8:381–405, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    Reilly RM. Radioimmunotherapy of malignancies. Clin Pharm 10:359–375, 1991.PubMedGoogle Scholar
  8. 8.
    Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G, Keenan AN, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J, Larson SM. Radioimmunoscintigraphy of colon cancer with I-131 B72.3 monoclonal antibody. J Nucl Med 29:1022–1030, 1988.PubMedGoogle Scholar
  9. 9.
    Mach JP, Buchegger F, Grob J, et al. Improved detection of colon carcinoma by using tomoscintigraphy and I-123 labeled F(ab’)2 and Fab fragments of anti-CEA monoclonal antibody. Br J Cancer 50:551, 1984.Google Scholar
  10. 10.
    Goldenberg DM, Blumenthal RD, Sharkey RM. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol 1:217–225, 1990.PubMedGoogle Scholar
  11. 11.
    Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl Med 306:517–519, 1982.CrossRefGoogle Scholar
  12. 12.
    Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147–3154, 1980.PubMedGoogle Scholar
  13. 13.
    Press O, Appelbaum F, Ledbetter J, et al. Monoclonal antibody 1F5 (anti-CD-20) serotherapy of human B cell lymphomas. Blood 69:584–591, 1987.PubMedGoogle Scholar
  14. 14.
    Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349–1363, 1985.PubMedGoogle Scholar
  15. 15.
    Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085–1093, 1984.PubMedGoogle Scholar
  16. 16.
    Dillman RO, Beuaregard JC, Shawler DL, Halpern SE, Markman M, Ryan KP, Baird SM, Clutter M. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Resp Modif 5:394–410, 1986.Google Scholar
  17. 17.
    Waldmann TA, Goldman CK, Bongiovanni KF, et al. Therapy of patients with human T-cell lymphotrophic virus-I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin 2. Blood 72:1805–1816, 1988.PubMedGoogle Scholar
  18. 18.
    Bunn PA, Carrasquillo JA, Keenan AM, et al. Successful imaging of malignant non-Hodgkin’s lymphoma using radiolabeled monoclonal antibody. Lancet 2:1219–1221, 1984.PubMedCrossRefGoogle Scholar
  19. 19.
    Carrasquillo JA, Bunn PA, Keenan AM, et al. Radioimmunodetection of cutaneous T-cell lymphoma with In-111 T101 monoclonal antibody. N Engl J Med 315:673–680, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Shawler DL, Miceli MC, Wormsley SB, et al. Induction of in vivo and in vitro antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res 44:5921–5927, 1984.PubMedGoogle Scholar
  21. 21.
    Carrasquillo JA, Mulshine IL, Bunn PA, et al. Tumor imaging of indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in cutaneous T-cell lymphoma. J Nuclear Med 28:281–287, 1987.Google Scholar
  22. 22.
    Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (Anti-CD37) antibody. J Clin Oncol 7:1027–1038, 1988.Google Scholar
  23. 23.
    De Nardo S, De Nardo C, O’Grady L, et al. Pilot studies of radioimmunotherapy of B cell Lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1:17–33, 1988.Google Scholar
  24. 24.
    Zimmer AM, Kaplan EH, Kazikiewiez JM, et al. Pharmacokinetics of I-131 T101 monoclonal antibodies in patients with chronic lymphocytic leukemia. Antibody Immunoconj Radiopharm 1:291–302, 1988.Google Scholar
  25. 25.
    Rosen S, Zimmer A, Goldman-Leikin R, et al. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an I-131-labeled monoclonal antibody: An Illinois Cancer Council study. J Clin Oncol 5:562–573, 1987.PubMedGoogle Scholar
  26. 26.
    Carde P, Manil L, da Costa L, et al. Hodgkin’s disease immunoscintigraphy: Use of the anti Reed-Stemberg cells H-RS-I monoclonal antibody in 9 patients. Proc Am Soc Clin Oncol 7:227, 1988.Google Scholar
  27. 27.
    Vriesendorp HM, Herpst JM, Leichner PK, Klein JL, Order S. Polyclonal yttrium-90 labeled antiferritin for refractory Hodgkin’s disease. Int J Rad Oncol 17:815–821, 1989.CrossRefGoogle Scholar
  28. 28.
    Lenhard R, Order S, Spunberg J, et al. Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin’s disease. J Clin Oncol 3:1296–1300, 1985.PubMedGoogle Scholar
  29. 29.
    Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I. Radioimmunotherapy of human B-cell lymphoma with Y-90 conjugated anti-idiotype monoclonal antibody. Cancer Res 50:1022s-1028s, 1990.Google Scholar
  30. 30.
    Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, Burger K, Swayne, Belisle E, Hansen HJ, Pinsky CM. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548–564, 1991.PubMedGoogle Scholar
  31. 31.
    Herlyn L, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumor antigens. Natl Cancer Inst 82:1183–1188, 1990.CrossRefGoogle Scholar
  32. 32.
    Knapp W, Dorken B, Rieber P, Schmidt RE, Stein H, von dem Borne AEGKR, eds. Leukocyte Typing IV. Oxford University Press, Oxford, 1989.Google Scholar
  33. 33.
    Link M, Bindl L, Meeker T, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 137:3013–3018, 1986.PubMedGoogle Scholar
  34. 34.
    Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47:830–840, 1987.PubMedGoogle Scholar
  35. 35.
    Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, et al. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 49:4568–4577, 1989.PubMedGoogle Scholar
  36. 36.
    Royston I, Majda JA, Baird SM, et al. Human T cell antigens defined by monoclonal antibodies: The 65,000 dalton antigen off T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol 57:553–564, 1980.Google Scholar
  37. 37.
    Robb RJ, Greene WC, Rusk CM. How and high affinity cellular receptors for interleukin 2, implications for the level of Tac antigen. J Exp Med 160:1126–1146, 1984.PubMedCrossRefGoogle Scholar
  38. 38.
    Ledbetter JA, Frankel AE, Herzenberg LA, Herzenberg HA. Human Leu T-cell differentiation antigen: Quantitative expression on normal lymphoid cells and cell lines. In: Research Monographs in Immunology, Vol 3, Monoclonal Antibody and T-Cell Hybridoma, GJ Hammerling, U Hammerling, JG Kearney (eds). 1981, pp. 16–22.Google Scholar
  39. 39.
    Pfreudshuh M, Mommertz E, Meissner M, et al. Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-I and HRS-2 react with activated cells of lymphoid and monocytoid origin. Cancer Res 8:217–224, 1988.Google Scholar
  40. 40.
    Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157–162, 1989.PubMedCrossRefGoogle Scholar
  41. 41.
    Agnarsson BA, Kadin ME. The immunophenotype of Reed-Sternberg cells. Cancer 63:2083–2087, 1989.PubMedCrossRefGoogle Scholar
  42. 42.
    Order SE, Porter M, Hellman S. Hodgkin’s disease: Evidence for a tumor-associated antigen. N Engl J Med 285:471–474, 1971.PubMedCrossRefGoogle Scholar
  43. 43.
    Sarcione EJ, Smalley JR, Lema MJ, Stutzman L. Increased ferritin synthesis and release by Hodgkin’s disease peripheral blood lymphocytes. Int J Cancer 20:339–346, 1977.PubMedCrossRefGoogle Scholar
  44. 44.
    Esphar Z, Order SE, Katz DH. Ferritin, a Hodgkin’s disease associated antigen. Proc Natl Acad Sci USA 71:39–56, 1974.Google Scholar
  45. 45.
    Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Ivest 67:134, 1981.Google Scholar
  46. 46.
    Freedman AS, Nadler LM. Cell surface markers in hematologic malignancies. Semin Oncol 14:193, 1987.Google Scholar
  47. 47.
    Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658–1665, 1985.PubMedCrossRefGoogle Scholar
  48. 48.
    Rudders RA, Levin A, Jespersen D, Zacks J, Delellis R, Ranger A, Krontiris T. Crossreacting human lymphoma idiotypes. Blood 80:1039–1044, 1992.PubMedGoogle Scholar
  49. 49.
    Steis GS, Carrasquillo JA, McCabe R, Bookman M, et al. An evaluation of the toxicity, immunogenicity, and tumor radioimmunodetection of two human monoclonal antibodies, 16.88 and 28A32 in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476–90, 1990.PubMedGoogle Scholar
  50. 50.
    Schroff RW, Farrell MM, Klein RA, Oldham RK, Foon KA. T65 antigen modulation in a phase 1 monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol 133:1641–1648, 1988.Google Scholar
  51. 51.
    Wang BS, Kelley KA, Lumanglas AL, Zimmer AM, Durr FE. Internalization and shedding of Lym-1 monoclonal antibody following interaction with surface antigens of a cultured human B-cell lymphoma. Cell Immunol 123:283–293, 1989.PubMedCrossRefGoogle Scholar
  52. 52.
    Naruki Y, Carrasquillo JA, Reynolds IC, et al. Differential cellular metabolism of In-111, Y-90 and I-125 radiolabeled T101, anti-CD5, monoclonal antibody. Nucl Med Biol 17:201–207, 1990.Google Scholar
  53. 53.
    Press OW, Farr AG, Borroz I, Anderson SK, Martin J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906–4912, 1989.PubMedGoogle Scholar
  54. 54.
    Press OW, Hansen JA, Farr A, Martin PJ. Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res 48:2249–2257, 1988.PubMedGoogle Scholar
  55. 55.
    Eary JF, Krohn KA, Kishore R, Nelp WB. Radiochemistry of halogenated antibodies. In: antibodies in Radiodiagnosis and Therapy, M Zalutsky (ed). CRC Press, Boca Raton, FL, 1989, pp. 84–102.Google Scholar
  56. 56.
    Srivastava SC, Mease RC. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Nucl Med Biol 18:589–603, 1991.Google Scholar
  57. 57.
    Eckelman WC, Paik CH. Labeling antibodies with metals using bifunctional chelates. In: antibodies in Radiodiagnosis and Therapy, MR Zalutzky (ed). CRC Press, Boca Raton, FL, 1989, pp. 103, 104-128.Google Scholar
  58. 58.
    Rhodes BA, Zamora PA, Newell KD, et al. Tc-99m labeling of murine monoclonal antibody fragments. J Nucl Med 27:685–693, 1986.PubMedGoogle Scholar
  59. 59.
    Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, DeNardo SJ, Snook D, Epenetos AA. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 62 (Suppl):21–26, 1990.Google Scholar
  60. 60.
    Gansow OA. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 18:369–381, 1991.Google Scholar
  61. 61.
    McCnonahey PH, Dixon FJ. A method of trace iodination of proteins for immunologic studies. Int Arch Aller 29:185–189, 1966.CrossRefGoogle Scholar
  62. 62.
    Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide, l,3,4,6-tetrachloro-3a, 6a-diphenylglycouril. Biochem Biophys Res Commun 80:849–857, 1978.PubMedCrossRefGoogle Scholar
  63. 63.
    Wilbur DS, Hadley SW, Hylarides MD, Abrams PG, Beaumier PA, Morgan AC, Reno JM, Fritzberg AR. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 30:216–226, 1989.PubMedGoogle Scholar
  64. 64.
    Garg PK, Slade SK, Harrison CL, Zalutsky MR. Labeling proteins using aryl iodide acylation agents: Influence of meta vs. para substitution on in vivo stability. Nucl Med Biol 16:669–673, 1989.Google Scholar
  65. 65.
    Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA, Jr., Attie AD. A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 212:791–800, 1983.PubMedGoogle Scholar
  66. 66.
    Ali SA, Warren SD, Richter KY, Badger CC, Eary JF, Press OW, Krohn KA, Bernstein ID, Nelp WB. Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate adducts. Cancer Res 50 (Suppl):783s-788s, 1990.Google Scholar
  67. 67.
    Westera G, Reist HW, Buchegger F, Heusser CH, Hardman N, Pfeiffer A, Sharma HL, Von Schulthess GK, Mach JP. Radioimmuno positron emission tomography with monoclonal antibodies: A new approach to quantifying in vivo tumor concentration and biodistribution for radioimmunotherapy. Nucl Med Commun 12:429–437, 1991.PubMedCrossRefGoogle Scholar
  68. 68.
    Finn R, Cheung NK, Divgi C, St. Germain J, et al. Technical challenges associated with the radiolabeling of monoclonal antibodies utilizing short-lived, positron emitting radionuclides. Int J Rad Appl Instrum [B] 18:9–13, 1991.Google Scholar
  69. 69.
    Krejcarek GE, Tucker KI. Covalent attachment of chelating groups to macromolecules. Biochem Biophys Res Commun 77:581–585, 1977.PubMedCrossRefGoogle Scholar
  70. 70.
    Hnatowich DJ, Childs RL, Lanteigne D, et al. The preparation of DTPA-coupled antibodies radiolabeled with metalli radionuclides: An improved method. J Immunol Methods 65:147–157, 1983.PubMedCrossRefGoogle Scholar
  71. 71.
    Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff B, Goldenberg DM, Hor G. Initial clinical results with Tc-99m labeled monoclonal antibody fragmen LL2 for radioimmunodetection of B-cell lymphomas. Antibody Immunoconj Radiopharm 5:334, 1992.Google Scholar
  72. 72.
    Schwarz A, Steinstrabber A. A novel approach to Tc-99m labeled monoclonal antibodies. J Nucl Med 28:721, 1987.Google Scholar
  73. 73.
    Carrasquillo JA, Kramer B, Fleisher T, Perentesis P, Boland CJ, Foss F, Rotman M, Reynolds JC, Mulshine JL, Camera L, Frincke J, Lollo C, Neumann RD, Larson SM, Raubitschek A. In-111 versus Y-90 T101 biodistribution in patients with hematopoietic malignancies. J Nucl Med 32:970, 1991.Google Scholar
  74. 74.
    Eary JF, Durack L, Williams D, Vanderheyden J-L. Considerations for imaging Re-188 and Re-186 isotopes. Clin Nucl Med 15:911–916, 1990.PubMedCrossRefGoogle Scholar
  75. 75.
    Sorenson JA, Phelps ME. The Anger camera basic principles. In: Physic in Nuclear Medicine Grune and Stratton, 1987, pp. 298–317.Google Scholar
  76. 76.
    Berche C, Mach JP, Lumbroso JD, et al. Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: First clinical results using radiolabeled monoclonal antibodies against carcinoembryonic antigen. Br Med J 285:1447–1451, 1982.CrossRefGoogle Scholar
  77. 77.
    Sorenson JA, Phelps ME. Nuclear medicine tomography principles. In: Physics in Nuclear Medicine Grune and Stratton, 1987, pp. 341–423.Google Scholar
  78. 78.
    De Nardo G, Macey SJ, De Nardo SJ, Zhang CG, Custer TR. Quantitative SPECT of uptake of monoclonal antibody. Semin Nucl Med 19:22–32, 1989.CrossRefGoogle Scholar
  79. 79.
    Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitaion of lesion radioactivity using external counting methods. Am Assoc Med Phys 3:253–255, 1976.Google Scholar
  80. 80.
    Myers MJ, Lavender JP, de Oliveira JB, Maseri A. A simplified method of quantitating organ uptake using a gamma camera. Br J Radiol 54:1062–1067, 1981.PubMedCrossRefGoogle Scholar
  81. 81.
    Hammond ND, Moldofsky PJ, Beardsley MR, Nulhern CB. External imaging techniques for quantitation of distribution of I-131 F(ab’)2 fragments of monoclonal antibody in humans. Med Phys 11:778–783, 1984.PubMedCrossRefGoogle Scholar
  82. 82.
    Eary JF, Appelbaum FL, Durack L, Brown P. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys 16:382–387, 1987.CrossRefGoogle Scholar
  83. 83.
    Loevinger R, Berman M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radiomuclides. MIRD pamphlet no 1 (revised). The Society of Nuclear Medicine, New York, 1976.Google Scholar
  84. 84.
    Snyder WS, Ford MR, Warner GG, et al.’ s’, Absorbed Dose per Unit Cumulation Activity of Selected Radionuclides and Organs. MIRD Pamphlet no 11. The Society of Nuclear Medicine, New York, 1975.Google Scholar
  85. 85.
    Loevinger R, Budinger TF, Watson EE in collaboration with MIRD Committee. MIRD Primer for Absorbed Dose Calculation. The Society of Nuclear Medicine, New York, 1988, pp. 1–128.Google Scholar
  86. 86.
    Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD: Radionuclide Data and Decay Schemes. The Society of Nuclear Medicine, New York, 1989, pp. 1–427.Google Scholar
  87. 87.
    Bernstein ID, Eary JF, Badger CC, Press OW, Appelbaum FR, Martin PJ, Krohn KA, Nelp WB, Porter B, Fisher D, Miller R, Brown S, Levy R, Thomas ED. High dose radiolabeled antibody therapy of lymphoma. Natl Cancer Inst 82:47–50, 1989.Google Scholar
  88. 88.
    Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller RA, Nelp WB, Bernstein ID. Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257–1268, 1990.PubMedGoogle Scholar
  89. 89.
    Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB, Krohn KA, Fisher D, Porter B, Thomas ED, Miller R, Brown S, Levy R, Bernstein ID. High-dose radioimmunotherapy of B-cell lymphomas. In: The Present and Future Role of Monoclonal Antibodies in the Management of Cancer, Vaeth JM, Meyer JL (eds). Front Radiat Ther Oncol 24:204–213, 1990.Google Scholar
  90. 90.
    Appelbaum FR. Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Hematol/Oncol Clini Norh Am 5:510–513, 1991.Google Scholar
  91. 91.
    Bernstein ID, Eary JF, Badger CC, Press OW, Appelbaum FR, Martin PJ, Krohn KA, Nelp WB, Porter B, Fisher D, Miller R, Brown S, Levy R, Thomas ED. High dose radiolabeled antibody therapy of lymphoma. Cancer Res 50 (Suppl):1017s-1021s, 1990.Google Scholar
  92. 92.
    Kaminski MS, Zasadny KR, Moon S, Roesner J, Milik AW, Butchko G, Glenn S, Wahl RL. Initial clinical radioimmunotherapy results with 131-I-Anti-B1 (Anti-CD20) in refractory B-cell lymphoma. Antibody Immunoconj Radiopharm 5:345, 1982.Google Scholar
  93. 93.
    De Nardo S, De Nardo G, O’Grady L, et al. Treatment of B cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer 3:96–101, 1988.Google Scholar
  94. 94.
    De Nardo GL, De Nardo SL, Meares CF, Kukis D, Diril H, McCall MJ, Adams GP, Mausner LF, Moody DC and Desphande SV. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibody Immunoconj Radiopharm 4:777–785, 1991.Google Scholar
  95. 95.
    De Nardo SJ, De Nardo GL, O’Grady LF, Macey DJ, Mills SL, Epstein AL, Peng J-S, McGahan JP. Treatment of a patient with B-cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 2:49–53, 1987.Google Scholar
  96. 96.
    De Nardo GL, De Nardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 131-I-Lym-1. Cancer Res 50 (Suppl): 1014s–1016s, 1990.Google Scholar
  97. 97.
    Chen D, HuE, Najafi A, Ansari A, Siegel M, Lee K, Watkins C, Payne D, Ma G, Hong K, Wong K, Miller G, Giffar S, Rosen P, Taylor C, Epatein A. Effects of preload on the pharmacokinetic and biodistribution of Lym-1 antibody in human. p. 41.Google Scholar
  98. Kaminski MS, Fig L, Zasadny KR, Koral KF, Del Rosario R, Miller R, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP, Moon S, Scott P, Miller RA, Wahl RL. Imaging, dosimetry and radioimmunotherapy with iodine-131 labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10:1696–1711, 1992.Google Scholar
  99. 99.
    Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ. A Phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma: Effects of tumor burden and antigen expression. J Clin Oncol 8:792–803, 1990.PubMedGoogle Scholar
  100. 100.
    Czuczman MS, Straus DJ, Divgi CR, Garin-Chesa P, Finn R, Graham M, Larson SM, Old LJ, Scheinberg DA. A Phase I dose escalation trial of 131-I-labeled monoclonal antibody OKB7 in patients with B cell lymphoma. Antibody Immunoconj Radiopharm 5:344, 1992.Google Scholar
  101. 101.
    Knowles DM, II, Tolidijian B, Marboe CC, et al. Distribution of antigens defined by OKB monoclonal antibodies on benign and malignant lymphoid cells and on non-lymphoid tissues. Blood 63:886–896, 1984.PubMedGoogle Scholar
  102. 102.
    Blend MJ, Seevers RH, Kozloff M, Hansen HJ, Sharkey RM, Goldenberg DM, Pinsky CM. Radioimmunodetection in patients with non-Hodgkin’s lymphoma using monoclonal antibody IMMU-LL2. Antibody Immunoconj Radiopharm 5:333, 1992.Google Scholar
  103. 103.
    Jones PL, Brown BA, Sands H. Uptake and metabolism of 111-In-labeled monoclonal antibody B6.2 by the rat liver. Cancer 50 (Suppl):852s-856s, 1990.Google Scholar
  104. 104.
    Miller RA, Maloney D, Warnke R, McDougall R, Wood G, Kawakami T, Dilley J, Goris ML, Levy R. Considerations for treatment with hybridoma antibodies. In: Hybridomas in Cancer Diagnosis and treatment, MS Mitchell, HF Oettgen (eds). Raven Press, New York, 1982, pp. 133–147.Google Scholar
  105. 105.
    Dillman RO, Sobol RE, Collins H, Beauregard J, Royston I. T101 monoclonal antibody therapy in chronic lymphocytic leukemia. In: Hybridomas in Cancer Diagnosis and Treatment. MS Mitchell, HF Oettgen (eds), Raven Press, New York, 1982, pp. 151–171.Google Scholar
  106. 106.
    Bunn PA, Jr. Edelson R, Ford SS, Shackney SE. Patterns of cell proliferation and cell migration in the Sezary syndrome. Blood 57:452–463, 1981.PubMedGoogle Scholar
  107. 107.
    Miller RA, Coleman CN, Fawcett HD, et al. Sezary syndrome: A model for migration of T lymphocytes to skin. N Engl J Med 303:89–92, 1980.PubMedCrossRefGoogle Scholar
  108. 108.
    Zimmer AM, Rosen ST, Spies SM, Goldman-Leikin R, Kazikiewicz JM, Silverstein EA, Kaplan EH. Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: Analysis of retreatment following plasmapheresis. J Nucl Med 29:174–180, 1988.PubMedGoogle Scholar
  109. 109.
    Rosen ST, Zimmer AM, Goldman-Leikin R, Kazikiewicz JM, Dykewicz MS, Silverstein EA, Spies SM, Kaplan EH. Progress in the treatment of cutaneous T cell lymphomas with radiolabeled monoclonal antibodies. Nucl Med Biol 16:667–668, 1989.Google Scholar
  110. 110.
    Carrasquillo JA, Foon KA, Mulshine JM, et al. Radioimmunoscintigraphy of chronic lymphocytes leukemia (CLL) with monoclonal antibodies. J Nucl Med 28:602, 1987.Google Scholar
  111. 111.
    Carde P, Pfreundschuh, da Costa L, Manil L, Lumbroso JD, Caillou B, Parmentier C, Saccavini JC, Diehl V. Radiolabeled monoclonal antibodies against Reed-Sternberg cells for in vivo imaging of Hodgkin’s disease by immunoscintigraphy. Recent Res Cancer Res 117:101–111, 1989.CrossRefGoogle Scholar
  112. 112.
    Carde P, Da Costa L, Manil L, Pfreundschuh M, Lumbroso J-D, Saccavini J-C, Caillou B, Ricard M, Boudet F, Hayat M, Diehl V, Parmentier C. Immunoscintigraphy of Hodgkin’s disease: In vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines. Eur J Cancer 26:474–479, 1990.PubMedCrossRefGoogle Scholar
  113. 113.
    Scheinberg DA, Lovett D, Divgi CH, Graham MC, Berman E, Pentlow K, Feirt K, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478–490, 1991.PubMedGoogle Scholar
  114. 114.
    Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 3:339–348, 1989.PubMedGoogle Scholar
  115. 115.
    Scheinberg DA, Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Old LJ, Larson SM. Dose escalation trial of I-131 M195 (anti-CD33) for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Antibody Immunoconj Radiopharm 5:345, 1992.Google Scholar
  116. 116.
    Weinstein IN, Parker RJ, Keenan AM, et al. Monoclonal antibodies in the lymphatics: Toward the diagnosis and therapy of tumor metastases. Science 218:1334–1337, 1982.PubMedCrossRefGoogle Scholar
  117. 117.
    Keenan AM, Weinstein JN, Mulshine IL, et al. Immuno-lymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium labeled T101 monoclonal antibody. J Nucl Med 28:4246, 1987.Google Scholar
  118. 118.
    Keenan AM, Weinstein JN, Carrasquillo JA, et al. Immunolymphoscintigraphy and the dose dependence of indium labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res 47:6093–6099, 1987.PubMedGoogle Scholar
  119. 119.
    Order S, Bloomer W, Jones A, et al. Radionuclide immunoglobulin lymphangiography. A case report. Cancer 35:1487, 1975.Google Scholar
  120. 120.
    Mulshine JL, Carrasquillo JA, Weinstein JM, et al. Direct intralymphatic injection of radio-labeled In-111T101 in patients with cutaneous T-cell lymphoma. Cancer Res 51:688–695, 1991.PubMedGoogle Scholar
  121. 121.
    Dillman RO, Beauregard JC, Halpern SE, Clutter M. Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J Biol Resp Modifiers 5:73–84, 1986.Google Scholar
  122. Reynolds JC, Del Vecchio S, Sakahara H, Lora ME, Carrasquillo JA, Neumann RD, Larson SM. Anti-murine antibody response to mouse monoclonal antibodies: Clinical findings and implications. Nucl Med Biol 16:121–125, 1989.Google Scholar
  123. 123.
    Dillman RO. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconj Radiopharm. 3:1–15, 1990.Google Scholar
  124. 124.
    Winter G, Milstein C. Man-made antibodies. Nature 349:293–299, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Jorge Carrasquillo

There are no affiliations available

Personalised recommendations